- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01345435
Effects of Telemonitoring and Telemedicine Service for Type 2 Diabetes Care (Smart-DM)
February 1, 2020 updated by: CHANGHEE LEE
A Multi-center, Randomized, Parallel, Interventional, Open Label Trial to Compare Hemoglobin A1C-lowering Effect of Conventional Treatment and Smart Care Service in Patients With Type 2 Diabetes
A multi-center, randomized, parallel, interventional, open label trial to compare Hemoglobin A1C-lowering effect of conventional treatment and Smart Care Service in patients with type 2 diabetes.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
- Objectives : To evaluate superiority in the Hemoglobin A1C -lowering effect of Smart Care Service compared to the conventional treatment in patients with type 2 diabetes.
Test and control group
- Control group : The subject group who is receiving any conventional treatment (hospital visit).
Test groups
- Conventional treatment + remote monitoring group: The subject group who is receiving the health care services using conventional treatment (hospital visit) and remote monitoring.
- Remote visit + remote monitoring group: The subject group who is receiving remote visit and remote monitoring using videotelephony
- Target Subject: Type II diabetes patients
Study Type
Interventional
Enrollment (Actual)
417
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Daegu, Korea, Republic of
- Kyungpook National University Hospital
-
Daegu, Korea, Republic of
- Yeungnam University Medical Center
-
Seoul, Korea, Republic of
- Gangnam Severance Hospital
-
Seoul, Korea, Republic of
- Yonsei University Health System
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 60 years (ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- More than 20 years of age and under 60 years of age
- Patients who are able to receive outpatient treatment with type II diabetes mellitus.
- If the patients require using insulin, patients who are using basal insulin or premixed insulin less than 2 times a day are eligible.
- Patients with HbA1c above 7% and less than 11% (7%≤HbA1c≤11%).
- Patients who are able to understand the purpose of this trial and to read and write.
- Patients who are able to use the Smart Care PC for this study.
- Patients who have wired/wireless internet access at home.
- Patients who participate voluntarily and sign the informed consent.
Exclusion Criteria:
- Patients with type I diabetes mellitus
- Patients who are using Bolus insulin (short-acting insulin) or insulin pump.
- Patients who take medicines which can significantly affect glycemic control.
- Patients with acute illness, untreated other disease or diabetic complications required additional treatment.
- Patients currently being hospitalized or planning to hospitalize during the study period.
- Patients who have severe renal disease (above 1.5 times the upper limit of normal serum creatinine levels).
- Pregnant or lactating women.
- Patients with any severe liver disease including cirrhosis (AST or ALT: above 3 times the upper limit of normal).
- Patients with uncontrolled chronic lung disease.
- Patients with known history of alcoholism, mental illness, or drug dependency.
- Patients who have cognitive disorder or psychiatric problems
- Patients who have participated in other clinical trial within 12 weeks prior to screening visit.
- Any clinically significant medical condition including neurologic disease, gastrointestinal disease or malignant tumor, etc., which may affect the test results, or any other medical condition which in the opinion of the investigator makes the patients unsuitable for participation in the trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: SUPPORTIVE_CARE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Telemonitoring group
|
The Telemonitoring group will be provided blood glucose meter, body composition analyzer, and remote monitoring PC.
They should visit the site once per every 2 months (8 weeks), and measure their blood glucose using a provided blood glucose monitor twice a day during study period (once after first morning urination and once before going to bed).
After measurement of blood glucose and body composition, the subjects should make transmit measured information through Smart Care PC into a centralized server of Smart Care Center.
At Smart care Center, care manager will provide remote blood glucose monitoring and individual diabetes case management
Other Names:
|
EXPERIMENTAL: Telemonitoring & Telemedicine group
|
The Telemonitoring & Telemedicine group will be provided blood glucose meter, body composition analyzer, and remote monitoring PC.
They should measure their blood glucose using a provided blood glucose monitor twice a day during the study period.
After measurement of blood glucose and body composition, the subjects should make transmit measured information through Smart Care PC into a centralized server of Smart Care Center.
At Smart care Center, care manager will provide remote blood glucose monitoring and individual diabetes case management.
A remote medical doctor should provide medical consultation to the subjects through videotelephony using the remote monitoring PC and then issue electronic prescriptions.
Other Names:
|
OTHER: Control group
|
The subjects who are assigned in the control group will be provided blood glucose Monitor.
The subjects who are assigned in the control group should perform the same blood glucose measurement same as the test group during the study, and measured results should be recorded in a diary of self blood glucose measurement.
In addition, the subjects should visit the site once per every two months (8 weeks).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in Hemoglobin A1c
Time Frame: 0 and 24 weeks
|
Changes in Hemoglobin A1c from baseline to 24 weeks visit. Reduce Hemoglobin A1c after study |
0 and 24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in FBS (Fasting blood sugar)
Time Frame: 0 and 24 weeks
|
Changes in FBS (Fasting blood sugar) from baseline to 24 weeks visit Maintains FBS within the normal range |
0 and 24 weeks
|
Changes in lipid profile
Time Frame: 0 and 24 weeks
|
Changes in lipid profile from baseline to 24 weeks visit Maintains normal lipid profile |
0 and 24 weeks
|
Percentage of subjects who achieved goal Hemoglobin A1c
Time Frame: 0 and 24 weeks
|
Goal Hemoglobin A1c <7%
|
0 and 24 weeks
|
Changes in body mass index (BMI)
Time Frame: 0 and 24 weeks
|
Reduction of body mass index - BMI=Body weight (kg)/Height2(m) |
0 and 24 weeks
|
SMBG(Self-monitoring of blood glucose) compliance
Time Frame: up to 24 weeks
|
measurement of Self-monitoring of blood glucose
|
up to 24 weeks
|
Changes in body weight
Time Frame: 0 and 24 weeks
|
Reduce body weight from baseline to 24 weeks visit
|
0 and 24 weeks
|
Assessment of patients' satisfaction
Time Frame: 24 weeks
|
Assessment of subjects' satisfaction, Only remote monitoring group and remote visit + remote monitoring group are applicable
|
24 weeks
|
Medication compliance
Time Frame: up to 24 weeks
|
|
up to 24 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: In Kyu Lee, M.D., Kyungpook National University Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2011
Primary Completion (ACTUAL)
April 1, 2013
Study Completion (ACTUAL)
December 1, 2013
Study Registration Dates
First Submitted
April 28, 2011
First Submitted That Met QC Criteria
April 29, 2011
First Posted (ESTIMATE)
May 2, 2011
Study Record Updates
Last Update Posted (ACTUAL)
February 5, 2020
Last Update Submitted That Met QC Criteria
February 1, 2020
Last Verified
February 1, 2020
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Smartcare-DM
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes
-
Antonio Di MauroCompletedType-2 DiabetesItaly
-
DiaMedica Therapeutics IncCompletedDiabetes Type 2Netherlands
-
RenJi HospitalUnknownType 2 Diabetes.China
-
University of Erlangen-Nürnberg Medical SchoolCompletedType 2-diabetesGermany
-
Chengdu Brilliant Pharmaceutical Co., Ltd.Not yet recruitingType 2 Diabetes Mellitus
-
Nanjing First Hospital, Nanjing Medical UniversityRecruitingType 2 Diabetes MellitusChina
-
Xiangya Hospital of Central South UniversityRecruitingType 2 Diabetes MellitusChina
-
University of Alabama at BirminghamCompletedType 2 Diabetes MellitusUnited States
-
Imperial College LondonAstraZeneca; Huma; North West London Collaboration of CCGs (NWL CCGs); Imperial...CompletedType 2 Diabetes MellitusUnited Kingdom
-
Universiti Sains MalaysiaCompleted
Clinical Trials on Telemonitoring group
-
Chang Hee, LeePurdue University; LG Electronics Inc.CompletedHypertensionKorea, Republic of
-
Chang Hee, LeePurdue University; LG Electronics Inc.CompletedObesity | Metabolic SyndromeKorea, Republic of
-
University of Sao PauloFederal University of São Paulo; Federal University of ParaíbaUnknownDental Caries in Children | Dental DiseasesBrazil
-
Aalborg University HospitalAalborg University; Steno Diabetes Center NordjyllandRecruiting
-
ResMedCompleted
-
Fundació Institut de Recerca de l'Hospital de la...Sociedad Española de Neumología y Cirugía Torácica; Societat Catalana de Pneumologia...RecruitingNon Invasive VentilationSpain
-
Istituto Auxologico ItalianoRecruiting
-
humanITcareUniversity of Barcelona; Hospital Universitario de Torrevieja; European Innovation...RecruitingHeart FailureSpain, Romania
-
Research and Practical Clinical Center for Diagnostics...Sechenov UniversityEnrolling by invitationInflammatory Bowel Diseases | Crohn Disease | Ulcerative ColitisRussian Federation
-
Hospital Universitari de BellvitgeInstitut d'Investigació Biomèdica de BellvitgeCompleted